News

Many patients with prostate cancer are treated with drugs that lower or block hormones that fuel tumor growth. While the drugs are effective for a time, most patients eventually develop resistance to these therapies. A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors.

Cold Spring Harbor Laboratory (CSHL) Associate Professor Pavel Osten and Professor Lloyd Trotman have developed a new way to study the life history of prostate cancer in mice. The pair combined their expertise in whole-organ imaging and prostate cancer to track how prostate cancer cells grow into tumors and spread to other organs. Their method

Prostate cancer screening results differ in men taking cholesterol-lowering statin drugs compared with non-users, a study conducted at Tampere University in Finland finds. In statin users, screening did not increase the incidence of prostate cancer as it did in other men. The study found the clearest difference in low-risk cancer, which is often overdiagnosed due

A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according to a study led by researchers at the University of California, Irvine. The team also identified ERV expression signatures that may be

A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A. Anna Ioannidou of Imperial College London, U.K., and colleagues present these findings in the open-access journal PLOS Medicine. Some factors associated with higher risk of prostate cancer cannot